thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Clinical Trial Design questions

Question 7 of 9 Intermediate Troubleshooting

How would you select between superiority, noninferiority and equivalence trial objectives?

Short answer

Superiority seeks evidence that treatments differ in the specified favorable direction. Noninferiority rules out a clinically unacceptable loss. Equivalence requires excluding important differences in either direction.

Why

The hypothesis and confidence-interval decision rule must match the clinical objective. Noninferiority requires a justified margin based on clinical relevance and credible active-control evidence, including assay sensitivity. Equivalence generally evaluates both bounds.

A nonsignificant superiority test does not establish noninferiority or equivalence.

How to work it through

  1. Start with treatment setting and why placebo or active control is appropriate.
  2. Define population, endpoint, intercurrent events and clinically meaningful effect.
  3. For noninferiority, justify the margin prospectively and preserve design features that would detect a meaningful loss of efficacy.
  4. Prespecify one- or two-sided error control, confidence-interval criteria and supportive analysis populations.
  5. For equivalence require both interval bounds to lie within prespecified margins.

An example

If treatment-minus-control benefit has a 95% CI of -3 to +1 and the justified noninferiority margin is -5, noninferiority may be supported under the prespecified test. This does not show the treatments are equivalent if the equivalence bounds were, for instance, ±2.

Where the answer stops holding

Poor adherence and cross-over may make treatments appear similar and bias noninferiority toward success. Margin choice can vary by endpoint and regulatory context. post-hoc margin selection undermines interpretability.

A strong answer covers

  • Superiority seeks evidence that treatments differ in the specified favorable direction
  • Noninferiority rules out a clinically unacceptable loss
  • Equivalence requires excluding important differences in either direction
  • Start with treatment setting and why placebo or active control is appropriate

Common mistakes

  • Declaring equivalence because p>0.05
  • Treating an arbitrary percentage as a margin
  • Ignoring ICH E9(R1) intercurrent events